OOIR: Observatory of International Research

Papers

(The TQCC of Expert Review of Hematology is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Are we closer to a standard of care for Richter’s syndrome? Novel treatments on the horizon	58
From bench to bedside: bridging the gaps in best practices for real-world chronic myeloid leukemia care	57
Treatment patterns and blood count control in 10,112 patients with polycythemia vera	52
Hematological parameters and X-ray exposure among medical radiation workers: a systematic review and meta-analysis	40
Frequencies of glycosylphosphatidylinositol (GPI)-deficient cells using high-sensitivity flow cytometry as per the 2018 ICCS/ESCCA consensus guideline in patients with hematologic malignancy, aplastic	35
What is the future of digital tools to help manage pain in sickle cell disease patients?	33
Do we need more guidance on thrombophilia testing? Challenges and special considerations	31
COVID-19 associated with immune thrombocytopenia: a systematic review and meta-analysis	29
Treating sickle cell disease in resource-limited sub-Saharan Africa: recent strategies and recommendations in addressing the gaps for the provision of evidence-based management	29
Hemophagocytic lymphohistiocytosis in Egyptian children: diagnosis, treatment challenges, and outcome	27
Upfront therapy for diffuse large B-cell lymphoma: looking beyond R-CHOP	23
Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia	21
The evolving management algorithm for the patient with newly diagnosed cold agglutinin disease	21
Immune thrombocytopenia and pregnancy: challenges and opportunities in diagnosis and management	21
Past, present, and future of orthopedic surgery in hemophilia: looking to a world without bleeding and arthropathy in the near future	18
Current trends and future artificial intelligence applications in transfusion medicine: a bibliometric analysis	17
Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B	17
Sickle cell disease and infertility risks: implications for counseling and care of affected girls and women	17
Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations	17
Correlation between hematocrit and the risk of common human cancers: results of a 1999–2020 observational survey and Mendelian randomization analysis	16
Late effects of hemopoietic stem cell transplant for sickle cell disease: monitoring and management	15
Allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: current status and future directions mainly focusing on a Chinese perspective	15
Extended post-discharge thromboprophylaxis in hospitalized COVID-19 patients	15
Evaluating ropeginterferon alfa-2b for the treatment of adults with polycythemia vera	14
BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia	13

Bone marrow aspirate or biopsy for multiple myeloma: when percentages matter!	12
Screening and interventional strategies for the late effects and toxicities of hematological malignancy treatments in pediatric survivors	12
Cost-effectiveness analysis of azacitidine maintenance therapy in patients with acute myeloid leukemia	12
The future of siRNA-mediated approaches to treat von Willebrand disease	12
Patient-centered care in von Willebrand disease: are we there yet?	12
Efanesoctocog alfa for the prevention and treatment of bleeding in patients with hemophilia A	12
Voxelotor for the treatment of sickle cell disease in pediatric patients	11
Managing blood supplies during natural disasters, humanitarian emergencies, and pandemics: lessons learned from COVID-19	11
Efficacy and safety of phosphatidylinositol 3-kinase inhibitors in patients with chronic lymphocytic leukemia: a meta-analysis and systematic review	11
BCL-2 inhibition in acute myeloid leukemia: resistance and combinations	11
Impact of atrial fibrillation in onco-hematological patients in Europe: a targeted literature review	11
New directions to develop therapies for people with hemophilia	11
Radiation therapy prior to CAR T-cell therapy in lymphoma: impact on patient outcomes	10
Thrombotic events in children and adolescent patients with SARS-CoV-2 infection: a systematic review with meta-analysis on incidence and management	10
Rivaroxaban plus aspirin after lower–extremity revascularization	10
DGPCNet: anemia detection from multimodal palm, fingernails, and eye conjunctiva images using deep global pyramid convolutional network	10
Development and internal validation of a prediction model for patients with hematologic diseases of fall risk: a cohort study	10
Optimizing long-term joint health in the treatment of hemophilia	10
The National Hemophilia Foundation’s State of the Science Research Summit: the foundation of a national research blueprint for inherited bleeding disorders	10
Emicizumab and unmet needs of patients with hemophilia a who are managed with replacement therapies	10
Is next-generation sequencing the future of measurable residual disease assays for Philadelphia chromosome-positive acute lymphoblastic leukemia?	10
Molecular targets for the treatment of AML in the forthcoming 5th World Health Organization Classification of Haematolymphoid Tumours	10
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: facilitating research through infrastructure, workforce, resources and funding	10
Pegcetacoplan: the first and only C3-targeted therapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria	9
Real-world treatment patterns and outcomes in people with von Willebrand disease treated prophylactically with recombinant von Willebrand factor in the United States	9
What is the importance of monitoring iron levels in different organs over time with magnetic resonance imaging in transfusion-dependent thalassemia patients?	9
Hematology in the post-COVID era: spotlight on vaccine-induced immune thrombotic thrombocytopenia and a conceptual framework (the 4P’s) for anti-PF4 diseases	9
Is the occurrence of deep vein thrombosis related to the fracture site? A two-sample Mendelian randomization study	9
Dose optimisation of ponatinib in chronic phase chronic myeloid leukemia	9
The association between hemoglobin level, anemia, and hypertension among adolescents in Sudan: a multicenter cross-sectional study	9
Bad players in AL amyloidosis in the current era of treatment	9
Role of volumetric analyses on [¹⁸F]FDG PET/CT in pediatric Hodgkin lymphoma	8
A review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDS	8
Oral decitabine in acute myeloid leukemia: assessing efficacy, safety, and future implications for older patients	8
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for mucocutaneous bleeding disorders	8
Hematological disorders in children with Down syndrome	8
A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitors	8
Long-term follow-up of patients with hairy cell leukemia in the south of Iran	8
Novel therapeutics for immune thrombocytopenia: an evolving treatment landscape	8
Mesenchymal stromal cells for the prophylaxis of graft-versus-host disease after hematopoietic stem cell transplantation: a meta-analysis of randomized controlled trials	8
The impact of oral health promotion on the quality of life of children with bleeding disorders: fighting misconceptions	8
Lived experience experts: a name created by us for us	8
Monoclonal antibodies used for the management of hemataological disorders	8
Revisiting the prognostic role of FLT3 mutations in acute myelogenous leukemia	8
Problems faced by people with hemophilia aged 18–35 years in social life: a qualitative study	7
Trends of chronic lymphocytic leukemia incidence and mortality in the United States: a population-based study over the last four decades	7
Advancements in targeting CD30 for lymphoma therapy: a historical perspective and future directions	7
Curative effect of motherwort combined with ethinylestradiol-cyproterone acetate on dysfunctional uterine bleeding	7
Pain in sickle cell disease: a prospective multicentre community-based cohort study in underserved Indian communities	7
An update on novel therapies for treating patients with arterial thrombosis	7

Novel mechanisms of action of emerging therapies of hereditary thrombotic thrombocytopenic purpura	7
Bridging the gap: how do we enroll more racial-ethnic minority patients in hematological drug trials?	7
Exploring health disparities in diagnosing multiple myeloma	7
Genetic variant of endothelial protein C receptor genes and its serum level in B thalassemic children	7
Sickle cell disease in gulf cooperation council countries: a systematic review	7
Advances in our understanding of genetic markers and targeted therapies for pediatric LCH	7
Indicators of an increased risk of therapy-related myeloid neoplasms in lymphoma patients: how can we best evaluate severe impairment of bone marrow function?	7
Pomalidomide combined with dexamethasone for the treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis	7
Evaluating quality-of-life outcomes during decitabine therapy in older adults with acute myeloid leukemia: overview of reported studies and assessment instruments	7
Navigating the gap between guidelines and practical challenges in selecting first-line therapy for chronic lymphocytic leukemia	6
An evaluation of mitapivat for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency	6
Circ_0035381 contributes to the progression of acute myeloid leukemia via regulating miR-186-5p/CDCA3 pathway	6
Revisiting the role of measurable residual disease in FLT3 mutated acute myelogenous leukemia	6
Avoiding serious treatment-emergent adverse events in Waldenström macroglobulinemia patients	6
Incidence, prevention and management of severe infections in patients undergoing therapy for chronic lymphocytic leukemia	6
Efficacy and safety evaluation of eptacog beta (coagulation factor VIIa [recombinant]-jncw) for the treatment of hemophilia A and B with inhibitors	6
A systematic literature review of the epidemiology, quality of life, and economic burden, including disease pathways and treatment patterns of relapsed/refractory classical Hodgkin lymphoma	6
Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin	6
Kompetitive allele specific PCR (KASP) based genotyping of sickle gene in the selected sub-ethnic tribal population of Gujarat and Madhya Pradesh	6
Identifying prognostic gene panels in acute myeloid leukemia	6
Reassuring clinicians and patients using SGLT-2 inhibitors: is there a need to worry about blood complications?	6
Targeting von Willebrand disease: the current status and future directions of management therapies	6
Challenges facing minimal residual disease testing for acute myeloid leukemia and promising strategies to overcome them	6
Understanding the interplay between chronic lymphocytic leukemia and type 2 diabetes	6
Challenges in the diagnosis of thrombotic thrombocytopenic purpura	6
May obesity increase the risk of lymphoma? Insights from genetic evidence	6
Development of CD30 CAR-T cells in refractory or relapsed Hodgkin’s lymphoma	6
Stem cell boost for immune effector cell associated hematotoxicity in multiple myeloma: minimizing long-term complications and expanding post CAR T-cell therapy relapse options	6
An observational study of disease management in adult patients with polycythemia vera: results from a large U.S. claims database	6
Real-world analysis and cost-effectiveness of iron chelation therapy adherence in transfusion-dependent thalassemia	6
Exploring the genetic relationship between deep vein thrombosis and plasma protein: a new research idea	6
A new decade awaits sticky platelet syndrome: where are we now, how do we manage and what are the complications?	5
Real-world treatment patterns and outcomes of triple-class treated patients with multiple myeloma in the United States	5
Anti-tissue factor pathway inhibitors for hemophilia: are these treatments the answer to overcoming current treatment limitations?	5
Effectiveness of myofascial therapy (MFT) along with traditional physiotherapy and intermittent prophylaxis on short-term improvement of joint health in hemophilic arthropathy: a randomized control tr	5
Secondary primary malignancies after treatment with chemo-immunotherapy in treatment-naïve patients with CLL: a systematic literature review	5
Vasculopathy among children and adolescents with sickle cell disease: the crosstalk with annexin A1, vitamin D, and myocardial iron overload	5
Modifiable lifestyle risk factors and survival after diagnosis with multiple myeloma	5
Immunotherapy for myelodysplastic syndrome and acute myeloid leukemia: where do we stand?	5
Five decades of successive establishment of hemophilia care in Thailand	5
Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia	5
Revolutionizing hypertension treatment: aprocitentan’s dual action against resistant hypertension	5
HIV-1 infection in sickle cell disease and sickle cell trait: role of iron and innate response	5
Proactive measures to reduce maternal mortality and post-partum hemorrhage in sub-Saharan Africa: the hematology perspective	5
Procalcitonin as a diagnostic marker for infection in sickle cell disease	5
Characterizing the ideal patient for treatment with inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: a systematic literature review	5
How clinicians and persons with hemophilia may approach shared decision-making	5
NSAIDS/COXIBS for the treatment of musculoskeletal pain secondary to hemophilic arthropathy	5
The role of staging in multiple myeloma	5